Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Pituitary masses and visual-field defects

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise optic chiasm and hormonal consequences of a sellar mass, prioritise cortisol and vision, and sequence MRI, formal perimetry, endocrine classification and specialist treatment safely.

  • A sellar mass may present through visual loss, headache, cranial nerve palsy, hormone excess, pituitary deficiency or incidental imaging; size alone does not establish clinical significance.
  • Upward expansion compresses the optic chiasm classically causing bitemporal field loss, but junctional, asymmetric or central defects occur and patients may not notice gradual peripheral change.
  • New or progressive visual acuity loss, field deterioration, diplopia or reduced consciousness requires urgent pituitary, ophthalmology and neurosurgical assessment rather than routine clinic surveillance.
  • Obtain dedicated contrast pituitary MRI and formal visual acuity, colour and field testing when the lesion approaches the optic apparatus or symptoms suggest compression.
  • Assess the full anterior pituitary, placing cortisol safety first; replace suspected ACTH deficiency before starting levothyroxine for central hypothyroidism.
  • Measure prolactin early and request dilution when a very large lesion has only a modest reported value, because assay hook effect can disguise a macroprolactinoma.
  • Functioning tumours need disease-specific biochemical confirmation: IGF-1 for acromegaly and validated cortisol testing for Cushing disease, not random growth hormone or cortisol alone.
  • Most prolactinomas are treated medically even with a macroadenoma, whereas compressive non-functioning adenomas commonly require transsphenoidal surgery; decisions belong in a pituitary MDT.

Key red flags

Thunderclap headache with visual loss, ophthalmoplegia, meningism or altered consciousness suggests pituitary apoplexy and requires immediate emergency management.

Haemodynamic instability, vomiting, hyponatraemia or hypoglycaemia in a patient with a sellar lesion may represent secondary adrenal insufficiency; give hydrocortisone without waiting when crisis is suspected.

Rapidly worsening acuity, colour vision or formal field defect requires same-day specialist discussion because delayed decompression can leave permanent optic damage.

Polyuria with hypernatraemia, impaired thirst or reduced consciousness signals dangerous water-balance failure needing monitored endocrine management.

A sellar lesion in known cancer, pregnancy, recent immunotherapy or systemic inflammatory disease broadens the urgent differential beyond a routine benign adenoma.

Investigation priorities

01
Dedicated contrast pituitary MRIFirst step

Define lesion compartment, optic relationship, cavernous extension, haemorrhage and differential morphology.

Management branches

VISIONNew visual defect with sellar mass

Visual field, acuity, colour or ocular-motor change suggests optic or cavernous compression.

  1. Document bedside acuity, pupils, fields, colour and eye movements, and ask specifically about sudden headache or altered consciousness.
  2. Check haemodynamics, glucose, sodium and urgent cortisol status, giving emergency hydrocortisone if apoplexy or adrenal failure is plausible.
  3. Arrange urgent pituitary MRI and formal neuro-ophthalmic testing while contacting the regional pituitary neurosurgical and endocrine team.
  4. Choose urgent decompression, dopamine agonist treatment or monitored conservative care according to apoplexy, tumour type and objective visual trajectory.

Key medicines

Hydrocortisone for central adrenal insufficiencyUse a physiological divided oral replacement regimen when stable, or immediate parenteral stress dosing when apoplexy, shock or failed absorption is suspected.Provide sick-day rules, card and emergency kit where indicated; do not use a reassuring TSH or normal potassium to exclude central cortisol deficiency.
CabergolineBegin the pituitary specialist's low weekly regimen with food and titrate against prolactin, visual recovery, tumour size and tolerability.Review postural symptoms, nausea, sleepiness, impulse-control or psychiatric change and fibrotic-valve monitoring under the current SmPC and local protocol.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • Society for Endocrinology pituitary guidanceUK clinical and emergency framework for pituitary disease.
  • NNUH pituitary tumour emergency guidelineNHS urgency, visual, prolactin and MRI pathway for sellar masses.
  • Leeds Pituitary Centre handbookNHS multidisciplinary diagnosis using hormone tests, formal fields and dedicated MRI.
  • NICE NG243 Adrenal insufficiencyCortisol recognition, replacement and emergency safety.
  • NHS England specialised endocrinologySpecialist provision for complex pituitary and hypothalamic disease.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewUnited Kingdom
Jurisdiction